IbuGel Forte is a prescription-strength topical gel containing ibuprofen 10% w/w — the highest-strength topical ibuprofen formulation available in the UK, twice the concentration of the 5% topical ibuprofen preparations available over the counter. It is a non-steroidal anti-inflammatory drug (NSAID) formulated specifically for percutaneous (through-skin) delivery, allowing ibuprofen to reach inflamed soft tissues, tendons, joints, and muscles locally while minimising the systemic absorption and gastrointestinal side effects associated with oral NSAID therapy. Topical NSAIDs are recommended as first-line treatment for localised musculoskeletal pain by NICE — preferred over oral NSAIDs for conditions such as osteoarthritis of the knee or hand and soft tissue injuries, due to their equivalent local efficacy with a significantly more favourable systemic safety profile. IbuGel Forte 10% is a prescription-only medication in the UK. Lower-strength topical ibuprofen preparations (5%) are available over the counter, but the higher-strength 10% formulation requires a clinician's assessment.

IbuGel Forte is indicated for:

IbuGel Forte's therapeutic effect is achieved through the same mechanism as oral ibuprofen, but delivered locally to the target tissue via percutaneous absorption: Topical penetration and local drug delivery: The gel formulation contains ibuprofen 10% in a vehicle designed to optimise skin penetration. After application and gentle massage into the skin, ibuprofen passes through the stratum corneum (the principal barrier to skin penetration) and accumulates in the underlying soft tissues, periarticular structures, and synovial fluid, achieving tissue concentrations substantially higher than those produced by equivalent oral dosing — with plasma concentrations that are typically less than 5% of those achieved with oral ibuprofen. Non-selective COX-1 and COX-2 inhibition at the target site: In inflamed tissues, ibuprofen inhibits both COX-1 and COX-2 isoforms of the cyclooxygenase enzyme, blocking the conversion of arachidonic acid to pro-inflammatory prostaglandins (PGE2, PGI2) and thromboxane A2. This reduces vasodilation, vascular permeability, sensitisation of peripheral nociceptors, and the production of pro-inflammatory mediators responsible for the swelling, heat, redness, and pain of musculoskeletal inflammation. Superior tissue-to-plasma ratio: The principal pharmacokinetic advantage of topical over oral NSAIDs is the ability to achieve high local tissue concentrations (often 5–10 times plasma levels) at the site of inflammation while maintaining very low systemic exposure — minimising the GI, renal, and cardiovascular risks of systemic NSAID therapy.

The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.

Always follow your clinician's instructions. Apply to the affected area only. Indication: Localised musculoskeletal pain and inflammation (adults and adolescents ≥14 years) 4–10 cm of gel (approximately 50–125 mg ibuprofen) per application site, up to 4 times daily, for 2 weeks for acute injury; up to 4 weeks for OA under clinical review. Administration Tips: Apply to clean, dry, intact skin only. Do not apply to broken, damaged, infected, or eczematous skin; do not use over open wounds or inflamed skin conditions. Massage gently into the affected area until the gel is absorbed. This improves penetration and drug delivery to underlying tissues. Wash hands thoroughly after application unless the hands are the area being treated. Avoid touching the eyes, mouth, or mucous membranes after handling the gel. Do not apply under occlusive dressings unless specifically directed, as this increases systemic absorption. Do not apply to large body surface areas. Limit application to the specific painful area; widespread application increases systemic absorption and associated risks. Avoid prolonged sun exposure to treated areas. Topical ibuprofen can cause mild photosensitivity at the application site.

Common Side Effects

[MAJOR] Oral NSAIDs and aspirin (anti-inflammatory doses) --- combination results in additive systemic NSAID exposure; increases GI, renal, and cardiovascular risk; do not combine. [MODERATE] Anticoagulants (warfarin, DOACs) --- even topical NSAIDs can have a small effect on platelet function and, with extensive application, on warfarin pharmacodynamics; monitor INR if adding IbuGel Forte in patients on anticoagulant therapy. [MODERATE] ACE inhibitors, ARBs, and diuretics --- with extensive application and significant systemic absorption, risk of renal impairment (triple whammy) is theoretically present; limit to small application areas and maintain hydration. [MINOR] Topical corticosteroids --- do not apply to the same area simultaneously; if both are prescribed, allow at least 30 minutes between applications to the same site.

Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.